NA Proactive news snapshot: Matinas BioPharma Holdings, Marrone Bio Innovations, Zynerba Pharmaceuticals, BioPorto, Mawson Resources UPDATE …

A glance at some of the day's highlights from the Proactive Investors US and Canada newswires


Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) shares surged in New York on Monday as the company outlined a raft of highlights in its first quarter to end March and said it had enough cash to sustain its operations into the second half. The specialty pharma company is developing novel transdermal CBD treatments for patients suffering rare epilepsies and neurological disorders. Looking ahead, the firm said: "Management believes that the cash runway is sufficient to fund operations and capital requirements beyond the expected NDA submission and potential approval of Zygel in FXS and into the second half of 2021."

BioPorto A/S (CPH:BIOPOR) has issued 2,150,000 warrants to its US corporate management and certain key employees. Each warrant grants the holder the right to subscribe for one share in the company. The exercise price is fixed at DKK 2.72 per share (US$0.39) corresponding to the last 10 days of volume-weighted average price of BioPorto’s stock. The warrants will be exercisable from May 11, 2022 to May 10, 2025. The program includes conditions on claw-back in case of erroneous financial information and on accelerated vesting in case of a change in control. The theoretical market value of the allocations of warrants amounts to DKK 2,005,031 (US$290,736). After this grant of warrants, the total number of outstanding warrants will be 18,682,500...

(Read more)